Efficacy and Safety of Tulobuterol Patch Combined With Tiotropium Bromide for Relieving Dyspnea Symptom of Chronic Obstructive Pulmonary Disease

Inclusion Criteria: * people aging from 40 to 80 with self ability of judgment * out-patients diagnosed as stable COPD according to "diagnosing and treatment guideline of COPD (2007 edition)" by Respiratory Department of Chinese Medical Association * PFT value at screen phase meet the standard as follows: FEV1/FVC \< 70% and FEV1% among 30%-80% 15 mins after inhalation of 400ug Ventolin (i.e., moderate and severe COPD patients ). * people who can use Tiotropium Bromide powder inhalation device * people who join the study voluntarily and sign ICF (Informed Consent Form) Exclusion Criteria: * people who have other acute or chronic respiratory diseases which may cause impairment of pulmonary function such as asthma * AECOPD （acute exacerbation of COPD） * people who got respiratory failure 1 month before the study * people who received oral corticoid treatment 1 month before the study * people who undergo oxygen therapy at home because of respiratory failure * people who are allergic to β2 receptor agonist such as tulobuterol * patients with Skin diseases such as atopic dermatitis, who are not appropriate to use transdermal patch * patients of hyperthyroidism, hypertension, heart disease and severe arrhythmia, diabetes mellitus, who are not appropriate to useβ2 receptor agonist * patients who have undergone pulmonary lobectomy or have tumor * active tuberculosis patients * people who got acute respiratory tract infection in a month or during screening phase * allergic rhinitis patients * glaucoma patients * people who have diseases which may cause dysuria such as prostatic hypertrophy or bladder neck occlusion * gestation, lactation and child-bearing age women who don't agree to take contraceptive measures during the study * people with abnormal live or kidney function, people with nervous system diseases, malignant tumor, neutropenia or other progressive basic diseases. * People who are mental retardation, mentally ill, deaf-mute or uncooperative, who cannot correctly describe their disease or do corresponding respiratory questionnaire. * People who are allergic to atropine and its derivatives (including tiotropium bromide and ipratropium bromide), lactose or any inhalant components. * people who have taken part in other medical clinical trial * other conditions that investigators think not appropriate for the study